N-Ethyl-cyclooctylamin | 68141-80-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Ethyl-cyclooctylamin
• 英文别名: N-ethylcyclooctanamine
• CAS: 68141-80-0
• 化学式: C₁₀H₂₁N
• mdl: MFCD09949522
• 分子量: 155.283
• InChiKey: ZBIUPFSTAYFOHV-UHFFFAOYSA-N

物化性质

• 沸点：
  211.2±8.0 °C(Predicted)
• 密度：
  0.84±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-Ethyl-cyclooctylamin 、 3-{2-[Benzyloxycarbonyl-(4-pyridin-4-yl-butyl)-amino]-ethyl}-2-(3,5-dimethyl-phenyl)-1H-indole-5-carboxylic acid 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 {2-[5-(Cyclooctyl-ethyl-carbamoyl)-2-(3,5-dimethyl-phenyl)-1H-indol-3-yl]-ethyl}-(4-pyridin-4-yl-butyl)-carbamic acid benzyl ester
  参考文献：
  名称：

  Potent nonpeptide GnRH receptor antagonists derived from substituted indole-5-carboxamides and -acetamides bearing a pyridine side-chain terminus

  摘要：

  A pyridine side-chain terminus has been incorporated into the indole-5-carboxamide and indole-5-acetamide series of GnRH antagonists. Potent activity was observed in binding and functional assays. Certain branched or cyclic tertiary amides were identified as preferred in each series. Alkylation of the side-chain secondary amine had generally unfavorable effects. Variations of the gem-dialkyl substituents in the indole-5-acetamide series were also investigated. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00275-x

文献信息

• Pyrrolo[2,3-d]pyrimidine compounds
  申请人：——

  公开号：US20020019526A1

  公开（公告）日：2002-02-14

  A compound of the formula 1 wherein R 1 , R 2 and R 3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

  一种化合物的结构式，其中R1、R2和R3如上所定义，它们是蛋白酪氨酸激酶的抑制剂，如Janus激酶3，因此可作为免疫抑制剂用于器官移植、狼疮、多发性硬化、类风湿性关节炎、牛皮癣、1型糖尿病和糖尿病并发症、癌症、哮喘、特应性皮炎、自身免疫性甲状腺疾病、溃疡性结肠炎、克罗恩病、阿尔茨海默病、白血病和其他自身免疫疾病的治疗。
• Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. III. N-Cyclohexyl-N-(2-hydroxyethyl)-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyramide and related compounds.
  作者：TAKAO NISHI、FUJIO TABUSA、TATSUYOSHI TANAKA、HIRAKI UEDA、TAKEFUMI SHIMIZU、TOSHIMI KANBE、YUKIO KIMURA、KAZUYUKI NAKAGAWA

  DOI：10.1248/cpb.31.852

  日期：——

  A series of N, N-disubstituted-ω-(1, 2-dihydro-2-oxoquinolyloxy) alkanecarboxamides was synthesized and tested for inhibitory activity towards collagen- and ADP-induced aggregation of rabbit blood platelet in vitro. These compounds were prepared by the reaction of ω-(1, 2-dihydro-2-oxoquinolyloxy) alkanoic acid and various amines by the mixed anhydride method. Among them, N-cyclohexyl-N-(2-hydroxyethyl)-4-(1, 2-dihydro-2-oxo-6-quinolyloxy) butyramide (IVa1) was found to have the most potent inhibitory activity. The structure-activity relationships are discussed.

  合成了一系列 N,N-取代的ω-(1, 2-二氢-2-氧羟喹啉氧基)烷基氨基酸酰胺，并对其在体外对胶原和ADP诱导的兔血小板聚集的抑制活性进行了测试。这些化合物是通过ω-(1, 2-二氢-2-氧羟喹啉氧基)烷酸与各种胺反应，采用混合酸酐法制备的。其中，N-环己基-N-(2-羟乙基)-4-(1, 2-二氢-2-氧-6-喹啉氧基)丁酰胺（IVa1）被发现具有最强的抑制活性。文中讨论了结构-活性关系。
• Pyrrolo [2,3-D] pyrimidine compounds
  申请人：Pfizer Inc.

  公开号：US20030212273A1

  公开（公告）日：2003-11-13

  A compound of the formula 1 wherein R 1 , R 2 and R 3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

  化合物的公式为1，其中R1，R2和R3的定义如上所述，它们是蛋白酪氨酸激酶的抑制剂，例如Janus Kinase 3，并且作为免疫抑制剂用于器官移植，狼疮，多发性硬化症，类风湿性关节炎，牛皮癣，1型糖尿病和糖尿病并发症，癌症，哮喘，特应性皮炎，自身免疫性甲状腺疾病，溃疡性结肠炎，克罗恩病，阿尔茨海默病，白血病和其他自身免疫性疾病的有用治疗方法。
• PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS
  申请人：Shigeta Yukihiro

  公开号：US20100286390A1

  公开（公告）日：2010-11-11

  Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.

  化合物(I)是一种新型的吡啶并嗪酮化合物，可以抑制嘌呤能P2X7受体，因此可用于预防、治疗和改善炎症和免疫性疾病。
• Process for disproportionating silanes
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0206621A1

  公开（公告）日：1986-12-30

  A process for disproportionating silanes, which comprises contacting a silane having at least one Si-H bond represented by the general formula wherein R represents an alkyl or aryl group, X represents a halogen atom or an alkoxy group, ℓis 0, 1 or 2, and m is 1, 2 or 3 and ℓ+m is 1, 2 or 3, and when fis 2, R's may be identical or different, and when ℓ+m is 1 or 2, X's may be identical or different, with a reaction product of a strong acid-type cation exchange resin with an amine.

  一种歧化硅烷的工艺，其包括与具有至少一个 Si-H 键的硅烷接触，该硅烷由通式表示 其中 R 代表烷基或芳基，X 代表卤素原子或烷氧基，ℓ 为 0、1 或 2，m 为 1、2 或 3，ℓ+m 为 1、2 或 3，当 f 为 2 时，R 可以相同或不同，当 ℓ+m 为 1 或 2 时，X 可以相同或不同。